title: Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration.
abstract: OBJECTIVE
  To summarize the current dosing strategies in the management of neovascular age-related macular degeneration with intravitreal injections of ranibizumab.
  
  
  RESULTS
  A variety of therapeutic strategies has been recently described as an alternative to the monthly fixed treatment. The efficacy and local and systemic safety results of each approach is relevant in order to make a clinical decision and to provide patients an accurate information.
  
  
  CONCLUSIONS
  The proposed therapeutic strategies achieve positive visual outcomes when compared with monthly fixed regimen in the clinical trials. However, the real-life practice does not reflect these results. The main cause of this difference is the incapability to adopt any of the different strategies as the clinics are completely booked and this turns into a delay in the diagnostic and treatment visits.
authors.affiliation: aUnit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia bRetics Oftared (RD12/0034), Prevention, early detection and treatment of the prevalent degenerative and chronic ocular pathology, Institute of Health Carlos III cDepartment of Ophthalmology, University Hospital Ramon y Cajal, Madrid dDepartment of Ophthalmology, University Clinic of Navarra, Pamplona, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: Marta S
authors.initials: MS
authors.lastname: Figueroa
authors.forename: Alfredo
authors.initials: A
authors.lastname: García-Layana
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab